ReShape Lifesciences Inc. announced that the Company will be holding a live-surgery surgical training for bariatric surgeons and key opinion leaders who will serve as investigators in the Company's
ReShape Lifesciences Inc. today announces that the United States Patent and Trademark Office (“USPTO”) has issued an Issue Notification for U.S. Patent Number 10010441 entitled “Gastric Restriction Device for Treating Obesity,” which covers a patent application regarding the Company’s Gastric Vest System (the “ReShape Vest”).
Results Show 14.7% Total Body Weight Loss at Twelve Months ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical…
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company and its products will be discussed during the Metabolic and Bariatric Sessions of the Minimally Invasive Surgery Symposium (MISS) taking place in Las Vegas from March 6-9, 2018.
According to the first study to quantify the proportion of cancers attributable to diabetes and high BMI published in The Lancet Diabetes & Endocrinology, diabetes and high BMI over 25 kg/m2 were the cause of 5.6 percent of new cancer cases worldwide.